Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing.

Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential ...

The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...